抗肿瘤药Dabrafenib 被引量：1

导出

摘要 Ras／Raf／MEK／ERK信号转导通路是调控细胞生长、分化和增殖最重要的通路之一，其中信号蛋白的过度表达或突变可导致肿瘤的发生和发展。如Raf激酶家族共包括3个成员—A．Raf、B—Raf和C—Raf，B—Raf在这3个成员中的突变率最高，约有7％～8％的人类肿瘤发生B-Raf 基因突变，而4-Raf 和c-R妒基因则较少发生突变。最具致命性的皮肤癌——黑色素瘤中B-Raf的突变率最高，约有40％～68％的转移性黑色素瘤发生这种突变，因此，

作者杨臻峥

出处《药学进展》 CAS 2013年第2期93-94,共2页 Progress in Pharmaceutical Sciences

关键词 dabrafenib 黑色素瘤 B-Raf抑制剂

分类号 R979.1 [医药卫生—药品]

引文网络
相关文献

同被引文献9

1KLEIN O,CLEMENTS A,MENZIES AM,et al.BRAF inhibitor activity in V600R metastatic melanoma[J].Eur J Cancer,2013,49(5):1073-1079.
2DENTON CL,MINTHORN E,CARSON SW,et al.Concomitant oral and intravenous pharmacokinetics of dabrafenib,a BRAF Inhibitor,in patients with BRAF V600 mutation-positive solid tumors[J].J Clin Pharmacol,2013,53(9):955-961.
3HAUSCHILD A,GROB JJ,DEMIDOV LV,et al.Dabrafenib in BRAF-mutated metastatic melanoma:a multicentre,openlabel,phase 3 randomised controlled trial[J].Lancet,2012,380(9839):358-365.
4GIBNEY GT,ZAGER JS.Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies[J].Expert Opin Drug Metab Toxicol,2013,9(7):893-899.
5LONG GV,TREFZER U,DAVIES MA,et al.Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain(BREAK-MB):a multicentre,openlabel,phase 2 trial[J].Lancet Oncol,2012,13(11):1087-1095.
6FALCHOOK GS,LONG GV,KURZROCK R,et al.Dabrafenib in patients with melanoma,untreated brain metastases,and other solid tumours:a phase 1 dose-escalation trial[J].Lancet,2012,379(9829):1893-1901.
7FLAHERTY KT,INFANTE JR,DAUD AN,et al.Combined BRAF and MEK inhibition in melanoma with BRAF V600mutations[J].N Engl J Med,2012,367(18):1694-1703.
8KING AJ,ARNONE MR,BLEAM MR,et al.Dabrafenib;preclinical characterization,increased efficacy when combined with trametinib,while BRAF/MEK tool combination reduced skin lesions[J].PLo S One,2013,8(7):e67583.
9王尔兵,王肇炎.恶性黑色素瘤的分子靶向药物治疗研究进展[J].医药导报,2012,31(10):1333-1336. 被引量：12